• Aurinia Pharmaceuticals Inc. recently initiated PRESERVE, a Phase 4 multicenter US study evaluating LUPKYNIS in combination with belimumab, obinutuzumab or anifrolumab in approximately 150 lupus nephritis patients, with complete renal response at 6 months as the primary endpoint.
• This trial directly tests whether combining the only FDA-approved oral lupus nephritis therapy with other approved biologics can refine future treatment regimens and usage patterns.
• We will now examine how testing LUPKYNIS in combination with other approved lupus nephritis therapies might influence Aurinia’s broader investment narrative.

AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Aurinia Pharmaceuticals Investment Narrative Recap

To own Aurinia today, you need to believe LUPKYNIS can sustain meaningful uptake in lupus nephritis while the company manages pricing pressure, competition, and a still-concentrated product base. The PRESERVE Phase 4 combo study looks incrementally supportive of the LUPKYNIS story, but it is unlikely to change the near term focus on execution against 2026 revenue guidance and on how management handles ongoing questions around LUPKYNIS exclusivity and generic challenges.

Among recent updates, the new AURORA 1 safety analysis presented at EULAR 2026 ties most directly into the PRESERVE news. By reinforcing LUPKYNIS’ profile on renal outcomes and treatment failure, it provides clinical context for why combination regimens are being tested and may help underpin current prescription trends, a key backdrop as Aurinia pursues combination data that could influence future guideline recommendations and usage patterns.

Yet, against this backdrop, investors should also be aware of the risk that any unexpected weakness in LUPKYNIS prescriptions could...

Aurinia Pharmaceuticals' narrative projects $461.3 million revenue and $176.3 million earnings by 2029.

Uncover how Aurinia Pharmaceuticals' forecasts yield a $17.00 fair value, in line with its current price.

Exploring Other Perspectives

More cautious analysts painted a very different picture, expecting earnings to fall to about US$62.7 million by 2029 and assuming shrinking margins, so you should weigh those assumptions against new data like PRESERVE and consider how your own expectations compare to these more pessimistic views.

Explore 7 other fair value estimates on Aurinia Pharmaceuticals - why the stock might be worth over 2x more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Aurinia Pharmaceuticals research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Aurinia Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Aurinia Pharmaceuticals' overall financial health at a glance.

Looking For Alternative Opportunities?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 30 best rare earth metal stocks of the very few that mine this essential strategic resource.
• The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.